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Background: Patient-maintained propofol TCI sedation (PMPS) allows patients to titrate their own target-controlled
infusion (TCI) delivery of propofol sedation using a handheld button. The aim of this RCT was to compare PMPS with
anaesthetist-controlled propofol TCI sedation (ACPS) in patients undergoing elective primary lower-limb arthroplasty
surgery under spinal anaesthesia.
Methods: In this single-centre open-label investigator-led study, adult patients were randomly assigned to either PMPS or
ACPS during their surgery. Both sedation regimes used Schnider effect-site TCI modelling. The primary outcomemeasure
was infusion rate adjusted for weight (expressed as mg kg1 h1). Secondary outcomes measures included depth of
sedation, occurrence of sedation-related adverse events and time to medical readiness for discharge from the post-
anaesthsia care unit (PACU).
Results: Eighty patients (48 female) were randomised. Subjects using PMPS used 39.3% less propofol during the sedation
period compared with subjects in group ACPS (1.56 [0.57] vs 2.57 [1.33] mg kg1 h1; P<0.001), experienced fewer discrete
episodes of deep sedation (0 vs 6; P¼0.0256), fewer airway/breathing adverse events (odds ratio [95% confidence interval]:
2.94 [1.31e6.64]; P¼0.009) and were ready for discharge from PACU more quickly (8.94 [5.5] vs 13.51 [7.2] min; P¼0.0027).
Conclusions: Patient-maintained propofol sedation during lower-limb arthroplasty under spinal anaesthesia results in
reduced drug exposure and fewer episodes of sedation-related adverse events compared with anaesthetist-controlled
propofol TCI sedation. To facilitate further investigation of this procedural sedation technique, PMPS-capable TCI infu-
sion devices should be submitted for regulatory approval for clinical use.
Clinical trial registration: ISRCTN29129799.
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2 - Hewson et al.Editor’s key points
 The authors developed a Medicines and Healthcare
products Regulatory Agency-approved patient-
maintained propofol sedation (PMPS) system that
gives patients control of the target concentration of a
propofol target-controlled infusion (TCI).
 They previously showed that patients using PMPS
were able to effectively sedate themselves without
adverse events andwith a high degree of satisfaction.
 The current study was an RCT comparing PMPS with
anaesthetist-controlled TCI propofol sedation.
 Patients in the PMPS group received 39% less propo-
fol, had fewer episodes of deep sedation and respi-
ratory impairment, and achieved PACU discharge
readiness sooner. which supports further develop-
ment of this approach.Procedural sedation facilitates diagnostic or therapeutic pro-
cedures, while reducing the negative patient experiences
associated with anxiety and pain.1 Sedation is commonly
achieved using propofol, delivered by target-controlled infu-
sion (TCI). Propofol TCI administration is typically titrated to
effect (i.e. depth of sedation) by anaesthetists supervising the
drug regimen, and such sedation is termed anaesthetist-
controlled propofol sedation (ACPS). For longer sedation epi-
sodes, ACPS offers a smoother and more titratable and pre-
dictable patient sedation compared with clinician-
administered intermittent bolus administration of propofol.
An alternative TCI propofol sedation technique is to allow
patients themselves to exert a degree of control over their
sedation depth, termed patient-maintained propofol sedation
(PMPS). Patient-maintained propofol sedation was first
described in 1997,2 and appears to facilitate safe and effective
procedural sedation in a variety of clinical settings.3e6 The
application of TCI technology differentiates PMPS from
patient-controlled propofol sedation (PCPS), which uses bolus
propofol administration (i.e. in mg) using non-TCI patient-
controlled devices. We have recently published a scoping re-
view on this topic, which identified that there is no commer-
cially available TCI device capable of PMPS and that the
literature is dominated by studies of PCPS.7 Although some
experimental evidence exists from three previously published
RCTs of PMPS (enrolling a total of 173 participants), our review
identified no previous trials testing PMPS against ACPS during
arthroplasty surgery. Our group therefore developed a PMPS-
capable research-ready infusion device to undertake this trial.
We conducted a prospective RCT with the aim of assessing
the clinical performance of PMPS in the setting of elective,
primary lower-limb arthroplasty performed under spinal
(subarachnoid) anaesthesia. The primary research objective
was to compare total propofol infusion rate adjusted for
weight when TCI sedation was patient-maintained vs when it
was anaesthetist controlled. Propofol infusion rate was chosen
as the primary outcome measure because it is a measurable
and clearly defined endpoint. It is also relatively free from
observer or reporting bias, both of which can affect the validity
of endpoints, such as patient satisfaction or depth of sedation,
when applied to clinical trials of sedation techniques. The
primary objective of the study, expressed as a null hypothesis(H0) was that there is no difference in propofol infusion rate
(normalised for body weight and sedation duration) when
sedation is patient maintained vs anaesthetist controlled.
Secondary objectives included examination of between-group
differences in calculated TCI model propofol compartment
concentrations, depth of sedation, patient-reported outcome
measures, occurrence of sedation-related adverse events, and
time and quality of recovery from sedation.
Methods
Trial design and oversight
This single-centre parallel-group open-label prospective
randomised study was conducted at Nottingham University
Hospitals NHS Trust. The study protocol was prospectively
approved by the UK NHS Research Ethics Committee Wales 6
on June 28, 2018 (reference: 18/WA/0190) and by the UK Med-
icines and Healthcare products Regulatory Agency on July 12,
2018 (reference: CI/2018/0035). The trial was registered on the
International Standard Randomised Controlled Trials Registry
on June 12, 2018 (reference: ISRCTN29129799). The full study
protocol and methodology underwent peer review and open-
access publication.8 Written consent was obtained from all
trial participants with the Nottingham University Hospitals
NHS Trust serving as study sponsor.Population
Adult patients (18 yr old) undergoing elective primary hip or
knee arthroplasty under spinal anaesthesia and expressing a
preference in the preoperative period for sedation during
surgery met the inclusion criteria for enrolment to this trial.
The exclusion criteria were any contraindication to spinal
anaesthesia, inability to use a handheld button for delivery of
PMPS, preoperative patient preference for surgery to be per-
formed awake or under general anaesthesia, BMI 42 kg m2
(male patients) or 37 kg m2 (female patients), or known al-
lergy to propofol. An upper limit for BMI was incorporated as
an exclusion criterion because of the known inaccuracies in
the performance of the Schnider model during maintenance
infusion in patients with high BMIs.9 The prototype PMPS-
capable infusion device used in this trial therefore replicates
the workaround found in some commercially available TCI
devices, of disallowing allometric data input which breaches
these BMI thresholds.10Randomisation
Following written consent, patients were randomly assigned,
using computer-generated block design, to ACPS or PMPS in a
1:1 ratio on the morning of surgery. Allocation concealment
was achieved by sequentially numbered opaque sealed enve-
lopes prepared by an individual who was not otherwise
involved in the conduct of this study. The next numbered
envelope was opened by a study investigator, and the ran-
domisation group revealed to the patient, investigator, and
clinical anaesthetist immediately after patient consent for
inclusion had been obtained on the morning of surgery.
Trial procedure
The full trial procedure, sedation regimes, and outcome mea-
sures have been previously published.8 In brief, screening for
eligibility and recruitment was conducted during routine clin-
ical preoperative anaesthetic assessment performed on the
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ticipants underwent randomisation on the morning of surgery
to either ACPS or PMPS for surgery. The participants were
provided with group-specific descriptions of their allocated
sedation regime. The safety of the participants in both groups
was supervised at all times by a study-independent clinical
anaesthetist who was not part of the investigative trial team.
On the morning of surgery, an investigator collected baseline
data, including previous experiences of surgery and anaes-
thesia, attitudes to medical care, the six-item abbreviated
Spielberger StateeTrait Anxiety Inventory (STAI),11 modified
Amsterdam Preoperative Anxiety and Information Scale,
abbreviated Krantz Health Opinion Survey,12 baseline Quality
of Recovery-15,13 and health-related utility scored using the
crosswalk valuation of EuroQoL® EQ-5D-5L responses.14,15 On
arrival in the operating suite, i.v. access and noninvasive
monitoring was secured, and a spinal anaesthetic was per-
formed by the independent clinical anaesthetist using hyper-
baric bupivacaine hydrochloride. After confirmation using
ethyl chloride spray of an adequate dermatomal sensory block,
the participants commenced their allocated sedation regime
using propofol 1% (Propofol-Lipuro® 1%; B. Braun, Melsungen,
Germany).All participants receivedsupplemental oxygen4e6L
min1 via a facemaskwith exhaled carbon dioxidemonitoring
(Sentri™; Intersurgical, Wokingham, UK). Ventilatory fre-
quency, arterial oxygen saturations, HR, and BP were recorded
at baseline and at 5-min intervals from the commencement of
sedation until the participant was deemed medically fit for
discharge from the PACU. This time was defined as a modified
Aldrete score16 of 9 or greater. Depth of sedationwasmeasured
at 5min intervals using theModified Observer’s Assessment of
Alertness and Sedation (mOAA/S) scale.17 The sedation regime
wasdiscontinued at the endof surgery once skin clips hadbeen
applied to the surgicalwound. In the PMPS group, the handheld
button was taken away from the participant and the PMPS
infusion was stopped. In the ACPS group, the TCI infusion was
stopped. The sedationperiodwas thusdefined as the time from
the commencement of sedation after spinal anaesthesia to the
discontinuation of sedation at the end of surgery. Once par-
ticipants were medically ready for discharge from PACU, a
group-specific postoperative questionnaire was administered.
This questionnaire sought feedback on participant experience,
including retrograde amnesia, and incorporated a trial-specific
unweighted version of the National Aeronautics and Space
Administration (NASA)TaskLoad Index18 toproducesubjective
self-reported workload estimates from users of the PMPS
regime with possible responses ranging from 0 (very low
workload) to 100 (very high workload). After discharge from
hospital, all participants were contacted by telephone to
conduct a final group-specific postoperative questionnaire. On
completion of telephone follow-up, the patient’s enrolment in
the trial was complete. Patients, outcome assessors, and su-
pervising clinical anaesthetists were not blinded to treatment
allocation in this open-label study.Pattient-controlled propofol sedation regime
Participants randomised to PMPS received sedation delivered
by a prototype PMPS-capable infusion device.19,20 A Latitude
5414 portable computer (Dell Technologies, Round Rock, TX,
USA) and a USB-connected handheld button (Ultimarc Ltd,
London, UK) were used to instruct a Perfusor® fm infusion
device (B. Braun, Melsungen) via an RS232 interface cable of
delivering the following PMPS regime:(i) A Schnider TCI model21 based on STANPUMP software
code implemented effect-site targeted infusion of propo-
fol, which commenced at 0.5 mg ml1 in all patients who
used PMPS.
(ii) The effect-site target concentration increased by 0.2 mg
ml1, if the patients pressed their handheld button, to a
maximum of 2.0 mg ml1, above which the effect-site
concentration could not be incremented.
(iii) After a button-induced increase in the effect-site target (a
‘successful’ button press), further button presses did not
increase the effect-site target concentration for 2 min (the
‘lockout period’).
(iv) If participants did not press the button for 15 min, the
effect-site target reduced by 0.1 mg ml1, and continued to
reduce by 0.1 mg ml1 every 15 min to a minimum of 0.5 mg
ml1 in the absence of a button press.
(v) If participants pressed their button within the lockout
period, or at the maximum allowable concentration of 2.0
mg ml1, this button press was recorded as ‘unsuccessful’.
Participants randomised to PMPS were given a stand-
ardised verbal instruction before and during sedation to ‘press
your button if you feel worried or you want to be more sleepy’.
Anaesthetist-controlled propofol sedation regime
Participants randomised to ACPS had their propofol sedation
controlled by the independent clinical anaesthetist, who was
not part of the trial team, using a Perfusor® Space (B. Braun
Melsungen AG) infusion device:
(i) The Schnider model effect-site target of propofol was
commenced at a concentration determined by the inde-
pendent clinical anaesthetist.
(ii) The anaesthetist incremented and decremented the pa-
tient’s effect-site target concentration as they saw fit based
on clinical judgement: no maximum or baseline levels
were pre-specified, and no particular depth of sedation
was specified as an endpoint.
Anaesthetists in control of ACPS were given a standardised
verbal instruction before and during sedation to ‘sedate the
patient according to your usual clinical practice for such a
case’.Outcomes
The primary trial outcome was total propofol infusion rate
expressed in milligrams and normalised for the confounders
of body weight and duration of sedation (mg kg1 h1). Sec-
ondary outcome measures included depth of sedation
measured onmOAA/S, change in patient anxiety measured by
psychological instruments described earlier, occurrence of
sedation-related adverse effects as defined by the Interna-
tional Committee for the Advancement of Procedural Sedation
Tracking and Reporting Outcomes of Procedural Sedation
(TROOPS) criteria,22 time to medical readiness for discharge
from PACU, and Quality of Recovery-15 scores.
Statistical analysis
The statistical analysis was performed based on a pre-
specified analysis plan.8 Continuous data were presented as
mean and 95% confidence interval (CI), or median and inter-
quartile range if not normally distributed. Binary data were
presented as frequency (%). Between-group differences in
normally distributed data were assessed for statistical
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to normal distribution, theManneWhitneyU-test was applied.
Non-random associations between categorical variables were
tested using a two-tailed Fisher’s exact test. Ordinal responses
recorded in Likert scale (e.g. perioperative anxiety and patient
satisfaction) were compared across trial arms using para-
metric methods suitable to underlying assumptions and non-
parametric methods, such as the Wilcoxon rank-sum test.
Quality of Recovery-15 scores were compared using Wilcoxon
matched pairs signed-rank test. An intention-to-treat analysis
was used to describe primary outcome data for all randomised
participants with complete primary outcome data.23,24 A per-
protocol analysis was conducted for secondary outcome var-
iables. All analyses were performed using SPSS version 26 (IBM
Corp., Armonk, NY, USA).Sample size calculation
A previous observational assessment demonstrated a mean
(standard deviation [SD]) normalised propofol infusion rate of
1.58 (0.76) mg kg1 h1 using PMPS in this population.6Assessed for elig
Randomise
Enrolment
• Received allocated intervention (n=40)
• Did not receive allocated intervention (n=0)
Allocated to ACPS (n=40)
Lost to follow-up (n=0)
Intention-to-treat analysis for primary
outcome (n=40)
Per-protocol analysis for secondary
outcomes (n=39)
• Protocol deviations
        ° Surgery cancelled after sedation




Fig 1. Consolidated Standards of Reporting Trials (CONSORT) flow dia
sedation; PMPS, patient-maintained propofol sedation.Prospectively gathered pilot data on routine clinical care at
our institution showed an equivalent infusion rate of 2.181
(0.915) mg kg1 h1 during ACPS for lower-limb arthroplasty.
We calculated that for a power of 90% and level of significance
of 5%, 72 participants would be required to detect an observed
difference in mean propofol infusion rate of 29% or greater
using Welch’s two-sided t-test. Anticipating a 10% participant
dropout, a total sample size of 80 was agreed.Results
Between September 18, 2018 and August 1, 2019, 98 people
were assessed for inclusion in the trial; 80 patients gave their
consent and were randomised into study groups.Participants
A Consolidated Standards of Reporting Trials (CONSORT)25
flow diagram of trial participants is shown in Figure 1. Base-
line participant, anaesthetic, and surgical characteristics are
summarised in Table 1.ibility (n=98)
d (n=80)
Excluded (n=18)
• Did not meet inclusion (n=5)
• Declined to participate (n=13)
Lost to follow-up (n=0)
• Received allocated intervention (n=38)
• Did not receive intervention (n=2)
  ° Unable to site spinal
  ° Consent withdrawn
Allocated to PMPS (n=40)
Intention-to-treat analysis for primary
outcome (n=38)
• Per-protocol analysis for secondary
  outcomes (n=37)
• Protocol deviations
        ° Technical device failure during
           sedation period (n=1)
-up
sis
gram of trial participants. ACPS, anaesthetist-controlled propofol
Table 1 Baseline, anaesthetic, and surgical characteristics. Data are presented as mean (standard deviation), median (inter-quartile
range [range]), or absolute number (%). ACPS, anaesthetist-controlled propofol sedation; PMPS, patient-maintained propofol sedation.
ACPS (n¼40) PMPS (n¼40) P-value
Age (yr) 71.5 [52e90] 72.5 [51e89] d
Sex (n)
Male 16 (40) 16 (40) d
Female 24 (60) 24 (60)
Total body weight (kg) 80.9 (15.0) 79.1 (16.0) d
Lean body mass (kg) 54.2 (10.0) 52.5 (10.4) d
Height (cm) 166 (9) 163 (10) d
BMI (kg m2) 29.3 (4.0) 29.6 (4.4) d
ASA physical status (n)
1 1 (2.5) 1 (2.5) d
2 27 (67.5) 26 (65.0)
3 11 (27.5) 13 (32.5)
4 1 (2.5) 0
Previous experience of medical or surgical procedures (n)
General anaesthesia 36 (90.0) 32 (80.0) d
Sedation 23 (57.5) 22 (55.0)
Awake 21 (52.5) 15 (37.5)
Patient-led sedation 1 (2.5) 0
Quality of life (EQ-5D-5L index) 0.799 (0.149) 0.695 (0.203) d
ACPS (n¼40) PMPS (n¼38) P-value
Midazolam before spinal anaesthesia (n) 20 (50) 9 (23) 0.013
Dose (mg) 1.5 (0.5) 1.4 (0.5) 0.656
Spinal hyperbaric bupivacaine (mg) 14 (13e15 [12e20]) 14 (13e15 [10e18.75]) 0.347
Spinal diamorphine (n) 10 (25.0) 12 (31.5) 0.617
Dose (mg) 0 (0e300 [300e500]) 0 (0e300 [300e500]) 0.638
Time taken to perform spinal (min) 1 (1e3 [0e25]) 1 (0e3 [0e32]) 0.904
Dermatomal spinal block height T8 (T8eT10 [T5eT10]) T9 (T6eT10 [T5eT10]) 0.826
Duration of sedation (min) 73 (22) 78 (17) 0.259
Duration of surgery (min) 59 (18) 63 (16) 0.297
Arthroplasty performed (n)
Hip 12 (30.0) 17 (44.7) 0.242
Knee 28 (70.0) 21 (55.2)
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sedation
Subjects using PMPS used 39.3% less propofol during the
sedation period compared with patients in group ACPS (1.56
[0.57] vs 2.57 [1.33] mg kg1 h1; P<0.001). The total dose of
propofol administered during the sedation period was
significantly lower in group PMPS vs ACPS (159 [92] vs 250
[177] mg; P¼0.006). The calculated effect-site concentrations
of propofol obtained by all patients who received ACPS and
those who received PMPS who used their button at least once
during surgery to increment their sedation are shown in
Figure 2. The sedation characteristics, including calculated
Schnider model calculated compartment concentrations and
depth of sedation obtained during the sedation period, are
shown in Table 2. mOAA/S scores of 2 or 3 were obtained by
29 ACPS-group patients for a total duration of 1500 min and
14 PMPS-group patients for a total duration of 535 min
(P<0.001). mOAA/S scores of 1 or 0 were obtained by six ACPS-
group patients for a total of 330 min and no PMPS-group pa-
tients. Median mOAA/S scores during sedation were 4 for
both PMPS and ACPS groups. In PACU, there was a higher
incidence of amnesia for the preceding sedation period
amongst subjects who received ACPS than in those who used
PMPS (11 [28%] vs 2 [5%]; P¼0.013).Button activation by PMPS users
The number of times subjects who used PMPS activated their
handheld button, requesting a deepening of sedation varied
as follows: 13 subjects used their button one to five times
during surgery, two subjects used their button six to 10 times,
and three subjects used the button 11 or more times. Nine-
teen out of 37 subjects in the PMPS group(51%) chose to make
no demands for an increase in sedation level using their
handheld PMPS button, and so remained at a propofol Cet of
0.5 mg ml1 throughout the sedation period. Unweighted
overall NASA Task Load Index for button usage in subjects
using PMPS was 7.5 out of a possible 100, indicating very low
perceived workload across the Task Load Index mental,
physical, temporal, performance, effort, and frustration do-
mains. There was no difference in NASA Task Load Index
scores between PMPS users who activated their button and
those who did not.Subject-reported outcome measures
Subject-reported outcome measures are summarised in
Figure 3. Patient responses demonstrated that the majority of
subjects in both groups had a very positive sedation expe-
rience, felt safe, and would recommend their sedation
0.0






































Fig 2. Calculated effect-site concentrations (Cet) of propofol over time. (a) Subjects who received ACPS (note single outlier administered
peak Cet of 5.0 mg ml1 removed). (b) Subjects who received PMPS who made one or two demands to increment their sedation. (c) Subjects
who received PMPS who made three or more demands to increment their sedation. In all plots, the Cet during sedation is represented as a
solid line, and the Cet after the discontinuation of sedation is represented by a dashed line. In (b) and (c), successful button activations are
represented by solid coloured circles. ACPS, anaesthetist-controlled propofol sedation; PMPS, patient-maintained propofol sedation.
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Table 2 Propofol dosing summary, sedation levels, and discharge times. Data are presented as mean (standard deviation), median
(inter-quartile range [range]), or absolute number (%). ACPS, anaesthetist-controlled propofol sedation; mOAA/S, Modified Observer’s
Assessment of Alertness and Sedation; PMPS, patient-maintained propofol sedation.
ACPS (n¼40) PMPS (n¼38) P-value
Calculated propofol concentration (mg ml1)
Mean effect site 1.1 (0.6) 0.6 (0.2) 0.0001
Peak effect site 1.3 (0.8) 0.8 (0.4) 0.0005
Mean plasma site 1.1 (0.6) 0.7 (0.3) 0.0011
Peak plasma site 2.7 (1.4) 1.9 (0.5) 0.0002
Depth of sedation (mOAA/S)
Maximum score (i.e. greatest wakefulness) 5 (5e5 [5e5]) 5 (5e5 [4e5]) 0.8451
Minimum score 3 (2e3 [0e5]) 4 (3e4 [2e5]) 0.0002
Episode of mOAA/S 1 or 0 6 (15%) 0 0.0256
Time to readiness for discharge from PACU (min) 13.5 (7.2) 8.9 (5.5) 0.0027
Patient-maintained propofol sedation for arthroplasty - 7technique to others. Participants using PMPS felt significantly
more in control of their sedation compared with those who
received ACPS (mean [SD] 11-point numerical rating scale
response 8.2 [3.7] vs 4.2 [4.5]; P<0.0001).
There were no statistically significant differences between
subjects who received ACPS or PMPS in their mean [SD] anxiety
(STAI) in the preoperative (19.0 [4.0] vs 18.4 [4.5]; P¼0.572),
PACU (22.4 [1.4] vs 23.0 [2.5]; P¼0.404), or postoperative phases
of care (20.9 [2.8] vs 20.3 [3.7]; P¼0.429).
There was no statistically significant difference in mean
(SD) Quality of Recovery-15 scores between subjects who
received ACPS or PMPS: 95.3 [8.4] vs 92.8 [11.5]; P¼0.2831,
when assessed at postoperative Days 7e10 by telephone
interview. These scores correspond to ‘moderate’ recovery
on the Kleif and G€ogenur26 QoR-15 scale and are in keeping
with previously published scores in the postoperative period
after joint arthroplasty.27 There was no statistically signifi-
cant difference in mean (SD) preoperative EQ-5D-5L health-
related utility scores between groups PMPS and ACPS (0.601
[0.207] vs 0.689 [0.218]; P¼0.066). At Days 7e10 postoperative
follow-up, mean (SD) health-related utility scores had
declined in both PMPS and ACPS groups; however, those
differences were not statistically significant (0.583 [0.225] vs
0.667 [0.179]; P¼0.744).Sedation-related adverse events
The incidences of airway, breathing, and circulatory sedation-
related adverse events, based on TROOPS criteria,22 are shown
in Table 3. Subjects sedated by ACPS had an increased risk of
airway/breathing adverse events compared with those
sedated using PMPS (odds ratio [95% CI]: 2.94 [1.31e6.64];
P¼0.009). The TROOPS-detected adverse events were limited to
the sedation period itself, and none resulted in permanent
harm. With the exception of midazolam administered at the
discretion of the treating anaesthetist before spinal anaes-
thesia, no patients in either trial arm received additional
sedative or analgesic medications during surgery.Discussion
Subjects undergoing lower-limb arthroplasty using the PMPS
regime used 39% less propofol than subjects undergoing ACPS.
Subjects using PMPS consequently experienced fewer in-
stances of deep sedation and airway/breathing sedation-related adverse events compared with subjects undergoing
ACPS. Subjects using PMPS experienced less amnesia andwere
ready for discharge from PACU more quickly than those
sedated by ACPS. Participants in both groups reported them-
selves highly satisfied with their sedation experience. There
were no detected differences in patient-reported satisfaction
or quality of recovery between the groups. Subjects rando-
mised to PMPS during their surgery reported very low NASA
Task Load Index scores for the sedation technique.
Context of results
There have been three previous RCTs of PMPS. Leitch and
colleagues5 compared the technique with clinician-bolus
midazolam sedation in oral surgery, Stonell and colleagues3
compared it with clinician-bolus propofol in colonoscopy,
and Rodrigo and colleagues4 compared it with PCPS in oral
surgery. Comparisons between studies require caution, as
each trial reported different propofol TCI models, compart-
ment targeting, PMPS algorithms, and outcome measures.
Nevertheless, the present finding that PMPS reduces propofol
infusion rates and depth of sedation compared with non-PMPS
procedural sedation is in keeping with all three previous
experimental investigations. This finding is similar to previ-
ously reported observations using PCPS techniques, including
in comparison with ACPS28 and fixed-rate propofol infusion.29
One possible explanation for the between-group difference
in propofol infusion rate is that patients using PMPS wanted
more sedation, but were unable to press their button suc-
cessfully and so used less propofol compared with ACPS;
however, this is unlikely because only one patient who
received PMPS achieved the algorithm ceiling effect-site con-
centration of 2.0 mg ml1. Furthermore, it is known that
healthy volunteers remain capable of activating handheld
buttons during PMPS despite effect-site concentrations of
propofol in excess of the 2.0 mgml1 ceiling used in our work.30
Another explanation is that patients using PMPS both wanted
and were capable of giving themselves more sedation, but
were reticent to do so (e.g. because of fear of ‘over-sedation’).
Again, this is not supported by patient feedback, which
showed that all patients felt safe and were positive about their
sedation experience. A further explanation may be that pa-
tient control is an important factor. Perhaps unsurprisingly,
patients using PMPS reported feeling significantly more in
control of their sedation compared with their ACPS counter-
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Fig 3. Patient-reported outcome measures. ACPS, anaesthetist-controlled propofol sedation; PMPS, patient-maintained propofol sedation.
8 - Hewson et al.can increase their sedation at any point is important, and
ownership of the locus of control means they request more
sedation only when actually required. A final explanationmay
be that anaesthetists delivering ACPS overestimate the
amount of propofol patients require to achieve satisfactory
sedation. This practice may arise from a fear that under-
sedation may result in patient complaint, as many patients
preoperatively express a desire to ‘not hear or see anything’
during their procedure. In the absence of significant medical
comorbidity or specific risk factors for complications of deep
sedation (such as obesity), clinicians may decide to cautiously
increase sedation depth for fear of leaving patients unsatisfied
with the experience. This trial was not designed to test
this hypothesis, but it is offered as one possible explanation
for the differences in practice seen between PMPS and ACPS
propofol usage.
Possible confounding factors in the relationship between
propofol administration and study outcome measures includethe block height achieved by spinal anaesthesia (higher blocks
are known to potentiate the sedative effects of propofol)31 and
the administration of additional non-propofol sedative agents
at the discretion of the supervising clinical anaesthetist. The
spinal anaesthesia block heights achieved for surgery were
similar between PMPS and ACPS groups (see Table 1); there-
fore, this is unlikely to play a significant role in subsequent
between-group differences in outcome measure. The admin-
istration of anxiolytic doses of midazolam (typically <25 mg
kg1) before spinal anaesthesia is recognised in clinical prac-
tice32 and was pragmatically accommodated into the trial
methodology at the discretion of the supervising independent
clinical anaesthetist. There was an unexpectedly higher inci-
dence of midazolam administration in group ACPS, although
the doses administered did not differ between groups, as re-
ported in Table 1. Midazolam is known to influence the phar-
macodynamics33 and pharmacokinetics34 of propofol, but
such interactions are described at larger midazolam doses
Table 3 Airway, breathing, and circulatory sedation-related adverse events. Data presented as absolute number (n) of discrete events
recorded; doses presented as median (range). ACPS, anaesthetist-controlled propofol sedation; COPD, chronic obstructive pulmonary
disease; PMPS, patient-maintained propofol sedation.
ACPS (n¼39) PMPS (n¼37) P-value
Minor airway or breathing
Supplemental oxygen (>6 L min1) 1 0 d
Airway repositioning (chin lift/jaw thrust) 4 0 d
Tactile stimulation 0 0 d
Suctioning for hypersalivation 0 0 d
Anticholinergic for hypersalivation 0 0 d
Nasal airway 0 0 d
Intermediate airway or breathing
Positive-pressure ventilation 0 0 d
Naloxone or flumazenil 0 0 d
Oral airway 1 0 d
Sentinel airway or breathing
Tracheal intubation 0 0 d
Neuromuscular block 0 0 d
Pulmonary aspiration 0 0 d
Additional airway or breathing
Ventilatory frequency <8 bpm 11 5 d
Oxygen saturations <94% (88% if COPD) 6 3 d
Total airway/breathing adverse events 23 8 0.002
Intermediate circulatory
Bolus of i.v. fluid 0 0 d
Sentinel circulatory
Vasoactive drug administration
Glycopyrronium 1 1 d
Dose (mg) 400 200 d
Metaraminol 24 19 d
Dose (mg) 1.0 (0e4.5) 0.25 (0e3) d
Ephedrine 10 6 d
Dose (mg) 0 (0e27) 0 (0e18) d
Chest compressions 0 0 d
Death 0 0 d
Total circulatory adverse events 35 26 0.249
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interaction were to occur, we would expect this to cause
decreased propofol dosage in group ACPS than would other-
wise occur, and thereby make the trial null hypothesis more
difficult to reject.
The finding of the present study of fewer episodes of deep
sedation and airway/breathing-related complications using
PMPS is consistent with data presented in all three earlier
RCTs. Stonell and colleagues3 reported a mean [SD] number of
deep sedation events of 3.0 [3.2] in the anaesthetist-controlled
group vs 0.8 [1.4] in the PMPS group. Rodrigo and colleagues4
reported two episodes of deep sedation in the patient-
controlled non-TCI propofol infusion group vs zero in the
PMPS group, and Leitch and colleagues5 reported one episode
in the midazolam group vs zero in the PMPS group. This
consistent finding may be attributable to lower peak drug
concentrations compared with control arms, and also to the
programmed dose ceiling in PMPS algorithms, preventing pa-
tients from incrementing their sedation above a pre-
determined level. The feedback loop of reduced levels of
consciousness preventing patients from incrementing their
target concentrations of propofol even higher is another
explanation of the apparent safety of PMPS in this regard.
The occurrence of 23 airway and breathing and 35 circula-
tory adverse events during 40 episodes of ACPS sedation inpatients appears high, and some clinicians would likely view
their own sedation practice as not incurring such a high rate of
side-effects and complications. However, this trial has used
TROOPS adverse events reporting criteria for these events,
which detect and report with stringent criteria, including such
events as ventilatory frequency <8, which some clinicians in
their day-to-day practice may not consider adverse events.
Our trial reported medical readiness for discharge from
PACU using modified Aldrete scoring, with both groups
achieving medical readiness quickly after cessation of seda-
tion. This scoring system did not take into account the degree
of regression of spinal blockade, which will have continued to
regress after admission to the postoperative ward, as per the
usual practice of our centre.Study limitations
This study used an open-label design, placing the results at
risk of performance or observer bias affecting internal validity.
Although participant and anaesthetist blinding to group allo-
cation (using sham buttons) has been reported in a previous
trial of PMPS,3 other researchers have not blinded subjects,
arguing that a key component of PMPS is the element of con-
trol and empowerment that a handheld button provides, and
that this, in itself, may provide some of the psychological
10 - Hewson et al.benefit and anxiolysis for patients.35 If subjects who received
ACPS were given a button, this could alter their psychological
response to sedation, and provide additional anxiolysis and
comfort (or the reverse), meaning they are no longer receiving
normal ACPS. The clinical examination of PMPS is therefore
akin to the assessment of psychological therapies, such as
cognitive behavioural therapy, which are rarely blinded to
participants or healthcare staff. As a pragmatic evaluation of
PMPS in a ‘real-world’ clinical setting, the benefits of con-
ducting research in this environment needed to be weighed
against the practical restraints of doing so. One such restraint
is that effective blinding of outcome assessors to the inter-
vention received was deemed not feasible in this clinical
perioperative environment,6 and it is highly likely that
participant, supervising anaesthetist, and outcome assessor
unblinding would occur in the perioperative period because of
the physical restraints of the operating theatre and verbal
conversations giving clues to treatment identity. This is a well-
known limitation of effective blinding.36
To mitigate the risk of observer bias, the study used
objective outcome measures to test the trial hypotheses,
rather than novel or subjective outcome measurements. In
addition to providing more comprehensive reporting and
reducing observer bias, this will facilitate incorporation of the
study results into subsequent meta-analyses.7 These include
measured total propofol infusion rate adjusted for weight,
mOAA/S, TROOPS criteria for sedation-related side-effects,
modified Aldrete score, the NASA Task Load Index, and the
six-item Spielberger STAI. The study outcome measures
closely align with the recommendations of the Sedation Con-
sortium on Endpoints and Procedures for Treatment, Educa-
tion, and Research recommendations whose guidelines on
outcome measures in sedation trials were published after the
study methodology had been determined.37,38
Although this trial was conducted at a single UK centre, the
conduct of anaesthesia in both trial arms replicates the In-
ternational Consensus on Anaesthesia-Related Outcomes af-
ter Surgery Group recommendations,39 so we believe the trial
results have international external validity.
A further limitation is that this trial didnot seek feedback on
the quality of sedation provided from operating surgeons or
feedback from clinical anaesthetists on the usability of the
PMPS-capable infusion device. The rationale for decision-
making by anaesthetists regarding the administration of
additional sedatives (specifically midazolam in this trial) was
not requested as part of the current work. It is possible that the
lower administration of midazolam doses amongst partici-
pants randomised to PMPS may be a response by clinicians to
uncertainty regarding the safety or efficacy of PMPS as a seda-
tion technique. The extent to which clinician behaviour was
influenced by group allocation cannot be answered with cer-
tainty, as this feedback was not sought. Further specific
research should be conducted to obtain feedback from anaes-
thetists on the usability and functionality of PMPS as a sedation
technique administered by a PMPS-capable infusion device.
Conclusions
The findings of this study support the further advancement
of PMPS as offering an benefit to the perioperative care of pa-
tients undergoing hip or knee replacement under spinal
anaesthesia. Themain barrier to implementation of PMPS intoclinical practice is the current absence of a CE-marked com-
mercial infusion device capable of such sedation. It is likely
that this situation will change in the future, with device
manufacturers thought to be pursuing PMPS as a technology
for commercialisation, although the path from scientific
justification to international market adoption is slow and
tortuous in healthcare generally and with regard to TCI tech-
nology in particular.40Authors’ contributions
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